Ceftriaxone Use in Penicillin-Allergic Patients

Introduction to Ceftriaxone Safety

The American College of Allergy, Asthma, and Immunology recommends that patients with a penicillin allergy can generally take ceftriaxone, as it has a low cross-reactivity risk of approximately 2% 1, 2
Ceftriaxone is classified as a low-similarity-score cephalosporin with only 2.11% cross-reactivity risk (95% CI: 0.98-4.46%) in patients with proven penicillin allergy, according to the Journal of Allergy and Clinical Immunology 2, 3

The Dutch Working Party on Antibiotic Policy (SWAB) provides a strong recommendation (moderate quality evidence) that patients with suspected immediate-type penicillin allergy can receive cephalosporins with dissimilar side chains like ceftriaxone 1, 4
Ceftriaxone can be administered regardless of severity or timing of the original penicillin reaction, with consideration for monitored settings in cases of severe and recent reactions 1, 2, 4
For delayed-type reactions, ceftriaxone can be used without restriction, regardless of timing, with no special monitoring required 1, 5

History of severe delayed immunologic reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS syndrome) is a contraindication for ceftriaxone use 2, 3
History of organ-specific reactions (hemolytic anemia, drug-induced liver injury, acute interstitial nephritis) is also a contraindication for ceftriaxone use 2, 3
In these cases, all beta-lactam antibiotics should be avoided 2

Penicillin skin testing is not required before administering ceftriaxone, as the cross-reactivity risk is low 2, 3
Direct administration of ceftriaxone is appropriate due to the low cross-reactivity risk 1, 4

The Dutch Working Party on Antibiotic Policy provides a STRONG recommendation that patients with immediate-type penicillin allergy can receive cephalosporins with dissimilar side chains like ceftriaxone, regardless of severity or timing of the original reaction, in patients presenting with itching and swelling 6
Immediate-type reactions, including urticaria, angioedema, itching, and swelling occurring within 1-6 hours of penicillin exposure, are IgE-mediated but do NOT contraindicate ceftriaxone use, according to the Clinical Microbiology and Infection guideline 6

The Centers for Disease Control and Prevention recommends ceftriaxone 1-2 g IV daily for 10-14 days as an alternative treatment for syphilis in penicillin-allergic patients, although optimal dosing is not fully defined 7
Some specialists suggest ceftriaxone may be effective for early syphilis, with a recommended dose of 1 gram daily IM or IV for 8-10 days, based on limited clinical studies 8

For patients who have experienced a severe and recent penicillin reaction, the first dose of ceftriaxone should be given in a monitored clinical setting with trained personnel and emergency equipment readily available. 9

The FDA’s cautionary label stating that ceftriaxone “should be given cautiously to penicillin‑sensitive patients” reflects medicolegal concerns rather than evidence‑based contraindication, because strong guideline recommendations endorse its safe use in this population. 9

When prescribing ceftriaxone to a penicillin‑allergic individual, record the type and timing of the original penicillin reaction in the medical record to ensure appropriate clinical context. 9